Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 3/2018

01-03-2018 | Systematic Review

Relationship between Organizational Culture and the Use of Psychotropic Medicines in Nursing Homes: A Systematic Integrative Review

Authors: Mouna Sawan, Yun-Hee Jeon, Timothy F. Chen

Published in: Drugs & Aging | Issue 3/2018

Login to get access

Abstract

Background

Psychotropic medicines are commonly used in nursing homes, despite marginal clinical benefits and association with harm in the elderly. Organizational culture is proposed as a factor explaining the high-level use of psychotropic medicines. Schein describes three levels of culture: artifacts, espoused values, and basic assumptions.

Objective

This integrative review aimed to investigate the facets and role of organizational culture in the use of psychotropic medicines in nursing homes.

Method

Five databases were searched for qualitative, quantitative, and mixed method empirical studies up to 13 February 2017. Articles were included if they examined an aspect of organizational culture according to Schein’s theory and the use of psychotropic medicines in nursing homes for the management of behavioral and sleep disturbances in residents. Article screening and data extraction were performed independently by one reviewer and checked by the research team. The integrative review method, an approach similar to the method of constant comparison analysis was utilized for data analysis.

Results

Twenty-four studies met the inclusion criteria: 13 used quantitative methods, 9 used qualitative methods, 1 was quasi-qualitative, and 1 used mixed methods. Included studies were found to only address two aspects of organizational culture in relation to the use of psychotropic medicines: artifacts and espoused values. No studies addressed the basic assumptions, the unsaid taken-for-granted beliefs, which provide explanations for in/consistencies between the ideal use of psychotropic medicines and the actual use of psychotropic medicines.

Conclusions

Previous studies suggest that organizational culture influences the use of psychotropic medicines in nursing homes; however, what is known is descriptive of culture only at the surface level, that is the artifacts and espoused values. Hence, future research that explains the impact of the basic assumptions of culture on the use of psychotropic medicines is important.
Appendix
Available only for authorised users
Literature
1.
Seitz DP, Gill SS, Herrmann N, Brisbin S, Rapoport MJ, Rines J, et al. Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. Int Psychogeriatr. 2013;25(2):185–203.CrossRefPubMed
2.
Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359–69.CrossRefPubMed
3.
Bourgeois J, Elseviers MM, Bortel LV, Petrovic M, Vander Stichele RH. Sleep quality of benzodiazepine users in nursing homes: a comparative study with nonusers. Sleep Med. 2013;14(7):614–21.CrossRefPubMed
4.
Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;25(1):CD003476.
5.
Olazarán J, Valle D, Serra JA, Cano P, Muñiz R. Psychotropic medications and falls in nursing homes: a cross-sectional study. J Am Med Dir Assoc. 2013;14(3):213–7.CrossRefPubMed
6.
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.CrossRefPubMed
7.
Aparasu RR, Chatterjee S, Chen H. Risk of pneumonia in elderly nursing home residents using typical versus atypical antipsychotics. Ann Pharmacother. 2013;47(4):464–74.CrossRefPubMed
8.
Snowdon J, Galanos D, Vaswani D. Patterns of psychotropic medication use in nursing homes: surveys in Sydney, allowing comparisons over time and between countries. Int Psychogeriatr. 2011;23(9):1520–5.CrossRefPubMed
9.
Simoni-Wastila L, Wei YJ, Luong M, Franey C, Huang TY, Rattinger GB, et al. Quality of psychopharmacological medication use in nursing home residents. Res Soc Adm Pharm. 2014;10(3):494–507.CrossRef
10.
Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89–95.CrossRefPubMedPubMedCentral
11.
Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, et al. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012;32(1):11–7.CrossRefPubMed
12.
Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother. 2008;6(4):187–97.CrossRefPubMed
13.
Svarstad BL, Mount JK. Chronic benzodiazepine use in nursing homes: effects of federal guidelines, resident mix, and nurse staffing. J Am Geriatr Soc. 2001;49(12):1673–8.CrossRefPubMed
14.
Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care. 2000;38(12):1164–73.CrossRefPubMed
15.
Rochon PA, Stukel TA, Bronskill SE, Gomes T, Sykora K, Wodchis WP, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med. 2007;167(7):676–83.CrossRefPubMed
16.
Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behavior. Int Psychogeriatr. 2011;23(10):1632–9.CrossRefPubMed
17.
Cody M, Beck C, Svarstad BL. Challenges to the use of nonpharmacologic interventions in nursing homes. Psychiatr Serv. 2002;53(11):1402–6.CrossRefPubMed
18.
Schmidt I, Claesson CB, Westerholm B, Nilsson LG, Svarstad BL. The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes. J Am Geriatr Soc. 1998;46(1):77–82.CrossRefPubMed
19.
Alldred DP, Zermansky AG, Petty DR, Raynor DK, Freemantle N, Eastaugh J, et al. Clinical medication review by a pharmacist of elderly people living in care homes: pharmacist interventions. Int J Pharm Pract. 2007;15(2):93–9.CrossRef
20.
Thompson Coon J, Abbott R, Rogers M, Whear R, Pearson S, Lang I, et al. Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review. J Am Med Dir Assoc. 2014;15(10):706–18.CrossRefPubMed
21.
Li J, Porock D. Resident outcomes of person-centered care in long-term care: a narrative review of interventional research. Int J Nurs Stud. 2014;51(10):1395–415.CrossRefPubMed
22.
Nishtala PS, McLachlan AJ, Bell JS, Chen TF. Psychotropic prescribing in long-term care facilities: impact of medication reviews and educational interventions. Am J Geriatr Psychiatry. 2008;16(8):621–32.CrossRefPubMed
23.
Scott T, Mannion R, Davies H, Marshall M. The quantitative measurement of organizational culture in health care: a review of the available instruments. Health Serv Res. 2003;38(3):923–45.CrossRefPubMedPubMedCentral
24.
25.
Scott T, Mannion R, Davies HT, Marshall MN. Implementing culture change in health care: theory and practice. Int J Qual Health Care. 2003;15(2):111–8.CrossRefPubMed
26.
Davies H, Mannion R, Jacobs R, Powell A, Marshall M. Exploring the relationship between senior management team culture and hospital performance. Med Care Res Rev. 2007;64(1):46–65.CrossRefPubMed
27.
Hughes CM, Lapane K, Watson MC, Davies HTO. Does organisational culture influence prescribing in care homes for older people? A new direction for research. Drugs Aging. 2007;24(2):81–93.CrossRefPubMed
28.
Scott T, Mannion R, Marshall M, Davies H. Does organisational culture influence health care performance? A review of the evidence. J Health Serv Res Policy. 2003;8(2):105–17.CrossRefPubMed
29.
Schein EH. Organizational culture and leadership. 4th ed. San Francisco, CA: Jossey-Bass; 2010.
30.
Schein EH. Coming to a new awareness of organizational culture. Sloan Manag Rev. 1984;25(2):3–16.
31.
Schein EH. Sense and nonsense about culture and climate. In: Ashkanasy NM, Wilderom CPM, Peterson MF, editors. Handbook of organizational culture & climate. Thousand Oaks: Sage; 2000. p. xxiii–xxx.
32.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral
33.
Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546–53.CrossRefPubMed
34.
Dixon-Woods M, Fitzpatrick R, Roberts K. Including qualitative research in systematic reviews: opportunities and problems. J Eval Clin Pract. 2001;7(2):125–33.CrossRefPubMed
35.
Stowasser DA, Allinson YM, O’Leary M. Understanding the medicines management pathway. J Pharm Pract Res. 2004;34(4):293–6.CrossRef
36.
Cohen-Mansfield J, Jensen B. Physicians’ perceptions of their role in treating dementia-related behavior problems in the nursing home: actual practice and the ideal. J Am Med Dir Assoc. 2008;9(8):552–7.CrossRefPubMed
37.
Cohen-Mansfield J, Jensen B. Nursing home physicians’ knowledge of and attitudes toward nonpharmacological interventions for treatment of behavioral disturbances associated with dementia. J Am Med Dir Assoc. 2008;9(7):491–8.CrossRefPubMed
38.
Cohen-Mansfield J, Jensen B. Assessment and treatment approaches for behavioral disturbances associated with dementia in the nursing home: self-reports of physicians’ practices. J Am Med Dir Assoc. 2008;9(6):406–13.CrossRefPubMed
39.
Sawan M, Jeon YH, Fois RA, Chen TF. Exploring the link between organizational climate and the use of psychotropic medicines in nursing homes: a qualitative study. Res Social Adm Pharm. 2017;13(3):513–23.CrossRefPubMed
40.
Sawan MJ, Jeon YH, Fois RJ, Chen TF. A qualitative study exploring visible components of organizational culture: what influences the use of psychotropic medicines in nursing homes? Int Psychogeriatr. 2016;28(10):1725–35.CrossRefPubMed
41.
Ellis ML, Molinari V, Dobbs D, Smith K, Hyer K. Assessing approaches and barriers to reduce antipsychotic drug use in Florida nursing homes. Aging Mental Health. 2015;19(6):507–16.CrossRefPubMed
42.
Lemay CA, Mazor KM, Field TS, Donovan J, Kanaan A, Briesacher BA, et al. Knowledge of and perceived need for evidence-based education about antipsychotic medications among nursing home leadership and staff. J Am Med Dir Assoc. 2013;14(12):895–900.CrossRefPubMed
43.
Mort JR, Singh YN, Gaspar PM, Adams PL, Singh NN. Attitudes and knowledge of long term care nurses toward psychotropic medication for the elderly. Clin Gerontol. 1993;12(3):13–31.CrossRef
44.
Svarstad BL, Mount JK, Bigelow W. Variations in the treatment culture of nursing homes and responses to regulations to reduce drug use. Psychiatr Serv. 2001;52(5):666–72.CrossRefPubMed
45.
Thurmond JA. Nurses’ perceptions of chemical restraint use in long-term care. Appl Nurs Res. 1999;12(3):159–62.CrossRefPubMed
46.
Ervin K, Finlayson S, Cross M. The management of behavioural problems associated with dementia in rural aged care. Collegian. 2012;19(2):85–95.CrossRefPubMed
47.
Smith MA, Simpson JM, Benrimoj SI. General practitioner acceptance of medication review in Sydney nursing homes. J Pharm Pract Res. 2002;32(3):227–31.CrossRef
48.
Hughes CM, Goldie R. “I just take what i am given” adherence and resident involvement in decision making on medicines in nursing homes for older people: a qualitative survey. Drugs Aging. 2009;26(6):505–17.CrossRefPubMed
49.
Patterson SM, Hughes CM, Lapane KL. Assessment of a United States pharmaceutical care model for nursing homes in the United Kingdom. Pharm World Sci. 2007;29(5):517–25.CrossRefPubMed
50.
Shaw C, McCormack B, Hughes CM. Prescribing of psychoactive drugs for older people in nursing homes: an analysis of treatment culture. Drugs Real World Outcomes. 2016;3(1):121–3.CrossRefPubMedCentral
51.
Wood-Mitchell A, James IA, Waterworth A, Swann A, Ballard C. Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age Ageing. 2008;37(5):547–52.CrossRefPubMed
52.
Cornege-Blokland E, Kleijer BC, Hertogh CM, van Marum RJ. Reasons to prescribe antipsychotics for the behavioral symptoms of dementia: a survey in Dutch nursing homes among physicians, nurses, and family caregivers. J Am Med Dir Assoc. 2012;13(1):80.e1–6.CrossRefPubMed
53.
Janus SIM, van Manen JG, Ijzerman MJ, Bisseling M, Drossaert CHC, Zuidema SU. Determinants of the nurses’ and nursing assistants’ request for antipsychotics for people with dementia. Int Psychogeriatr. 2017;29(3):475–84.CrossRefPubMed
54.
Smeets CHW, Smalbrugge M, Zuidema SU, Derksen E, de Vries E, van der Spek K, et al. Factors related to psychotropic drug prescription for neuropsychiatric symptoms in nursing home residents with dementia. J Am Med Dir Assoc. 2014;15(11):835–40.CrossRefPubMed
55.
Anthierens S, Grypdonck M, De Pauw L, Christiaens T. Perceptions of nurses in nursing homes on the usage of benzodiazepines. J Clin Nurs. 2009;18(22):3098–106.CrossRefPubMed
56.
Azermai M, Vander Stichele RR, Van Bortel LM, Elseviers MM. Barriers to antipsychotic discontinuation in nursing homes: an exploratory study. Aging Mental Health. 2014;18(3):346–53.CrossRefPubMed
57.
Bourgeois J, Elseviers MM, Azermai M, Van Bortel L, Petrovic M, Vander Stichele RR. Barriers to discontinuation of chronic benzodiazepine use in nursing home residents: perceptions of general practitioners and nurses. Eur Geriatr Med. 2014;5(3):181–7.CrossRef
58.
Flick U, Garms-Homolova V, Rohnsch G. “And mostly they have a need for sleeping pills”: Physicians’ views on treatment of sleep disorders with drugs in nursing homes. J Aging Stud. 2012;26(4):484–94.CrossRefPubMed
59.
Lhermite A, Munoz Sastre MT, Sorum PC, Mullet E. French lay people’s and health professionals’ views regarding the acceptability of involuntary treatment of nursing home residents. Int J Law Psychiatry. 2015;38:38–43.CrossRefPubMed
60.
Pekkarinen L, Elovainio M, Sinervo T, Finne-Soveri H, Noro A. Nursing working conditions in relation to restraint practices in long-term care units. Med Care. 2006;44(12):1114–20.CrossRefPubMed
61.
Peri K, Kerse N, Moyes S, Scahill S, Chen C, Hong JB, et al. Is psychotropic medication use related to organisational and treatment culture in residential care. J Health Organ Manag. 2015;29(7):1065–79.CrossRefPubMed
62.
Schmid IK, Svarstad BL. Nurse-physician communication and quality of drug use in Swedish nursing homes. Soc Sci Med. 2002;54(12):1767–77.CrossRef
63.
Hughes CM, Roughead E, Kerse N. Improving use of medicines for older people in long-term care: contrasting the policy approach of four countries. Healthc Policy. 2008;3(3):e154–67.PubMedPubMedCentral
64.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.CrossRef
65.
Sexton JB, Helmreich RL, Neilands TB, Rowan K, Vella K, Boyden J, et al. The Safety Attitudes Questionnaire: psychometric properties, benchmarking data, and emerging research. BMC Health Serv Res. 2006;6(1):44.CrossRefPubMedPubMedCentral
66.
Stein-Parbury J, Chenoweth L, Jeon YH, Brodaty H, Haas M, Norman R. Implementing person-centered care in residential dementia care. Clin Gerontol. 2012;35(5):404–24.CrossRef
67.
Beer C, Horner B, Almeida OP, Scherer S, Lautenschlager NT, Bretland N, et al. Current experiences and educational preferences of general practitioners and staff caring for people with dementia living in residential facilities. BMC Geriatr. 2009;9(1):1–8.CrossRef
68.
Scott-Cawiezell J, Jones K, Moore L, Vojir C. Nursing home culture: a critical component in sustained improvement. J Nurs Care Qual. 2005;20(4):341–8.CrossRefPubMed
69.
Nishtala PS, Hilmer SN, McLachlan AJ, Hannan PJ, Chen TF. Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis. Drugs Aging. 2009;26(8):677–86.CrossRefPubMed
70.
Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs. 2010;24(9):729–39.PubMed
71.
Verrue CL, Petrovic M, Mehuys E, Remon JP, Vander Stichele R. Pharmacists’ interventions for optimization of medication use in nursing homes: a systematic review. Drugs Aging. 2009;26(1):37–49.CrossRefPubMed
72.
Aiken LH, Cimiotti JP, Sloane DM, Smith HL, Flynn L, Neff DF. Effects of nurse staffing and nurse education on patient deaths in hospitals with different nurse work environments. Med Care. 2011;49(12):1047–53.CrossRefPubMedPubMedCentral
73.
Estabrooks CA, Midodzi WK, Cummings GG, Ricker KL, Giovannetti P. The impact of hospital nursing characteristics on 30-day mortality. J Nurs Adm. 2011;41(7–8 Suppl):S58–68.CrossRefPubMed
74.
Hewison A. Organizational culture: a useful concept for nurse managers? J Nurs Manag. 1996;4(1):3–9.CrossRefPubMed
Metadata
Title
Relationship between Organizational Culture and the Use of Psychotropic Medicines in Nursing Homes: A Systematic Integrative Review
Authors
Mouna Sawan
Yun-Hee Jeon
Timothy F. Chen
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 3/2018
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-018-0527-5

Other articles of this Issue 3/2018

Drugs & Aging 3/2018 Go to the issue

Original Research Article

Safety of Injectable HPβCD-Diclofenac in Older Patients with Acute Moderate-to-Severe Postoperative Pain: A Pooled Analysis of Three Phase III Trials

Author Correction

Author Correction to: Denosumab: A Review in Postmenopausal Osteoporosis

short communication

Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic Burden

Review Article

Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails

Systematic Review

Do Risk Prediction Models for Postoperative Delirium Consider Patients’ Preoperative Medication Use?

Original Research Article

Prescription Changes During Geriatric Care Episodes: A Trend Analysis Conducted in Sweden

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits